Microchip implanted in pancreatic tumors could personalize chemo choices

NCT ID NCT07254091

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests a tiny implantable device that delivers microdoses of several chemotherapy drugs directly into pancreatic tumors during surgery. The device is removed after four hours, and the surrounding tissue is analyzed to see which drugs worked best. Ten adults with pancreatic cancer who are already scheduled for surgery will take part. The main goal is to check safety, but researchers also hope to learn whether this approach can guide personalized treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

microdevice containing microdoses of chemotherapy drugs (doxorubicin, gemcitabine, paclitaxel, 5-fluorouracil, oxaliplatin, irinotecan)

What this could lead to

If successful, this device could help doctors quickly identify which chemotherapy drugs work best for each patient's pancreatic cancer, leading to more personalized treatment.

What could go wrong

This is a very early safety study with only 10 participants. The device is experimental and may not provide useful drug response data. There is a risk of complications from implantation and removal.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Zuckerberg Cancer Center

    RECRUITING

    New Hyde Park, New York, 11040, United States